[go: up one dir, main page]

WO2008132568A3 - Fusion proteins binding to growth factors - Google Patents

Fusion proteins binding to growth factors Download PDF

Info

Publication number
WO2008132568A3
WO2008132568A3 PCT/IB2008/000901 IB2008000901W WO2008132568A3 WO 2008132568 A3 WO2008132568 A3 WO 2008132568A3 IB 2008000901 W IB2008000901 W IB 2008000901W WO 2008132568 A3 WO2008132568 A3 WO 2008132568A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
growth factors
fusion proteins
proteins binding
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/000901
Other languages
French (fr)
Other versions
WO2008132568A2 (en
Inventor
Hak-Zoo Kim
Young Jun Koh
Ho-Min Kim
Keehoon Jung
Choonjoo Jeon
Gou Young Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genexel Sein Inc
Original Assignee
Genexel Sein Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020097020284A priority Critical patent/KR101220245B1/en
Application filed by Genexel Sein Inc filed Critical Genexel Sein Inc
Priority to DK08788817.8T priority patent/DK2126092T3/en
Priority to CA2679658A priority patent/CA2679658C/en
Priority to EP08788817.8A priority patent/EP2126092B1/en
Priority to ES08788817T priority patent/ES2688623T3/en
Priority to CN200880013111.9A priority patent/CN101679988B/en
Priority to AU2008243928A priority patent/AU2008243928B2/en
Priority to JP2009551284A priority patent/JP5564268B2/en
Publication of WO2008132568A2 publication Critical patent/WO2008132568A2/en
Publication of WO2008132568A3 publication Critical patent/WO2008132568A3/en
Priority to IL200593A priority patent/IL200593B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)

Abstract

The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding two different growth factors polypeptide components. Such a polypeptide is capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide.
PCT/IB2008/000901 2007-02-27 2008-02-27 Fusion proteins binding to growth factors Ceased WO2008132568A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2009551284A JP5564268B2 (en) 2007-02-27 2008-02-27 Fusion proteins that bind growth factors
DK08788817.8T DK2126092T3 (en) 2007-02-27 2008-02-27 FUSION PROTEINS BINDING TO GROWTH FACTORS
CA2679658A CA2679658C (en) 2007-02-27 2008-02-27 Fusion proteins binding to growth factors
EP08788817.8A EP2126092B1 (en) 2007-02-27 2008-02-27 Fusion proteins binding to growth factors
ES08788817T ES2688623T3 (en) 2007-02-27 2008-02-27 Fusion proteins that bind to growth factors
KR1020097020284A KR101220245B1 (en) 2007-02-27 2008-02-27 Fusion Proteins Binding to Growth Factors
AU2008243928A AU2008243928B2 (en) 2007-02-27 2008-02-27 Fusion proteins binding to growth factors
CN200880013111.9A CN101679988B (en) 2007-02-27 2008-02-27 Fusion proteins that bind growth factors
IL200593A IL200593B (en) 2007-02-27 2009-08-26 Fusion proteins binding to growth factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89176907P 2007-02-27 2007-02-27
US60/891,769 2007-02-27

Publications (2)

Publication Number Publication Date
WO2008132568A2 WO2008132568A2 (en) 2008-11-06
WO2008132568A3 true WO2008132568A3 (en) 2008-12-31

Family

ID=39795468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/000901 Ceased WO2008132568A2 (en) 2007-02-27 2008-02-27 Fusion proteins binding to growth factors

Country Status (11)

Country Link
US (1) US10259860B2 (en)
EP (1) EP2126092B1 (en)
JP (2) JP5564268B2 (en)
KR (1) KR101220245B1 (en)
CN (2) CN108546301B (en)
AU (1) AU2008243928B2 (en)
CA (1) CA2679658C (en)
DK (1) DK2126092T3 (en)
ES (1) ES2688623T3 (en)
IL (1) IL200593B (en)
WO (1) WO2008132568A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
MX2010007357A (en) 2008-01-03 2011-03-03 The Scripps Res Institute Star Antibody targeting through a modular recognition domain.
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102219859B (en) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 Fusion protein for antagonizing angiogenesis inducible factor and application thereof
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2013033561A1 (en) * 2011-08-31 2013-03-07 Integrated Diagnostics, Inc. Vegf-specific capture agents, compositions and methods of using and making
HRP20181595T1 (en) 2012-07-13 2018-12-14 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
GB201223053D0 (en) * 2012-12-20 2013-02-06 Medical Res Council Receptor
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
KR102060187B1 (en) 2013-07-19 2019-12-27 삼성전자주식회사 Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102196450B1 (en) 2013-09-17 2020-12-30 삼성전자주식회사 Anticancer composition containing an anti-Ang2 antibody inducing binding to Tie2 receptor
KR20150063728A (en) * 2013-12-02 2015-06-10 삼성전자주식회사 Anti-VEGF-C/anti-Ang2 bispecific antibody
KR101819135B1 (en) * 2014-03-18 2018-01-18 한국과학기술원 Glycosylated VEGF Decoy Receptor Fusion Protein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (en) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
EP3454903A4 (en) * 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS
KR20190031246A (en) 2016-07-20 2019-03-25 에르피오 세러퓨틱스 인코포레이티드 Humanized monoclonal antibody targeting VE-PTP (HPTP-beta)
JP2021514656A (en) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． IL-6 antibody and its fusion constructs and conjugates
CN112912104A (en) * 2018-08-17 2021-06-04 三钰生物科技股份有限公司 Anti-angiogenesis fusion protein and application thereof
CN113164597B (en) * 2018-09-24 2025-02-28 视点制药公司 Multispecific antibodies targeting HPTP-β (VE-PTP) and VEGF
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
TWI865587B (en) 2019-12-06 2024-12-11 美商再生元醫藥公司 Anti-vegf protein compositions and methods for producing the same
KR102426802B1 (en) * 2019-12-23 2022-07-28 한국프라임제약주식회사 A pharmaceutical composition comprising VEGFR fusion protein for preventing and treating angiogenesis related disease
KR20230008830A (en) 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 VEGF traps and mini-traps and methods of treating eye disorders and cancer
AU2022251523A1 (en) * 2021-03-31 2023-09-28 Hangzhou Exegenesis Bio Ltd. Fusion molecules targeting vegf and angiopoietin and uses thereof
WO2023016449A1 (en) * 2021-08-09 2023-02-16 成都原菩生物技术有限公司 Bispecific fusion polypeptide and application thereof
KR20230105972A (en) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 ANTI-C3b ANTIBODY OR ANTI-C5 ANTIBODY CONJUGATED WITH ANGIOGENESIS INHIBITOR AND USE THEREOF
CN114262683B (en) * 2022-03-01 2022-06-17 中国科学院动物研究所 Bacterial preparation for expressing VEGFR 3D 2 polypeptide and construction method and application thereof
WO2023199951A1 (en) * 2022-04-13 2023-10-19 株式会社セルージョン Multipotent stem cell having anti-vegf function and differentiated cell thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044453A1 (en) * 1996-05-07 1997-11-27 Genentech, Inc. Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
WO2006043972A1 (en) * 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
WO2006113277A2 (en) * 2005-04-13 2006-10-26 Cell Genesys, Inc. Multivalent soluble tyrokinase receptor that bind angiogenic factor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
DK1292335T3 (en) * 2000-06-23 2007-09-17 Bayer Schering Pharma Ag Combinations and compositions that interfere with VEGF / VEGF and angiopoietin / Tie receptor function and their use (II)
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US7700318B2 (en) * 2004-08-25 2010-04-20 Amprotein Corporation Chimeric polypeptide and use thereof
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
KR102060187B1 (en) * 2013-07-19 2019-12-27 삼성전자주식회사 Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044453A1 (en) * 1996-05-07 1997-11-27 Genentech, Inc. Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
WO2006043972A1 (en) * 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
WO2006113277A2 (en) * 2005-04-13 2006-10-26 Cell Genesys, Inc. Multivalent soluble tyrokinase receptor that bind angiogenic factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MESIANO ET AL.: "Role of Vascular Endothelial Growth Factor in Ovarian Cancer. Inhibition of Ascites Formation by Immunoneutralization", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 4, 1998, pages 1249 - 1256, XP000887067 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10927163B2 (en) 2007-12-21 2021-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US11993642B2 (en) 2009-04-07 2024-05-28 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US11673945B2 (en) 2009-06-16 2023-06-13 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US11407836B2 (en) 2012-06-27 2022-08-09 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US11999801B2 (en) 2014-12-03 2024-06-04 Hoffman-La Roche Inc. Multispecific antibodies

Also Published As

Publication number Publication date
WO2008132568A2 (en) 2008-11-06
CN101679988B (en) 2018-05-11
IL200593B (en) 2020-08-31
CA2679658C (en) 2018-11-27
US10259860B2 (en) 2019-04-16
IL200593A0 (en) 2011-08-01
CN108546301A (en) 2018-09-18
CN101679988A (en) 2010-03-24
AU2008243928B2 (en) 2012-08-09
US20080242587A1 (en) 2008-10-02
DK2126092T3 (en) 2018-10-22
JP5564268B2 (en) 2014-07-30
AU2008243928A1 (en) 2008-11-06
JP2010518871A (en) 2010-06-03
JP5952847B2 (en) 2016-07-13
EP2126092A4 (en) 2010-08-11
CN108546301B (en) 2021-09-07
KR101220245B1 (en) 2013-01-18
ES2688623T3 (en) 2018-11-05
EP2126092A2 (en) 2009-12-02
JP2014138602A (en) 2014-07-31
CA2679658A1 (en) 2008-11-06
KR20100005202A (en) 2010-01-14
EP2126092B1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
WO2008132568A3 (en) Fusion proteins binding to growth factors
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
EP3910065B8 (en) Interleukin -13 binding proteins
EP1984517B8 (en) Methods for modulating mannose content of recombinant proteins
IL210283A0 (en) Prostaglandin e2 binding proteins and uses thereof
WO2011133704A3 (en) Modified polypeptides and proteins and uses thereof
ZA201303003B (en) Single-chain multivalent binding proteins with effector function
IL198592A (en) Polypeptides binding 4ig-b7h3, nucleic acids encoding same and methods for production and use thereof
WO2008143679A9 (en) Nucleic acids and proteins and methods for making and using them
AU2009347206A8 (en) Isolation and purification of antibodies using Protein A affinity chromatography
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
WO2008127457A3 (en) Nucleic acids encoding recombinant protein a
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2008035217A3 (en) Fusion proteins comprising two or more igg binding domains of streptococcal protein g.
IL201445A0 (en) Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2011131510A3 (en) Selective modification of proteins
WO2012134416A3 (en) Peptide ligands
WO2009019441A3 (en) Granulocyte colony stimulating factor
WO2011055897A3 (en) Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same
WO2013085540A3 (en) Cry crystals for the production of antimicrobial proteins
WO2010067339A3 (en) Fusion protein capable of binding vegf-a and tnf-alpha
WO2009005871A3 (en) Novel optical labeling molecules in proteomics and other biological analyses
WO2009081170A3 (en) Peptide fusion proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013111.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788817

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008243928

Country of ref document: AU

Ref document number: 2679658

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200593

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009551284

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008243928

Country of ref document: AU

Date of ref document: 20080227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008788817

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097020284

Country of ref document: KR